Synthorx, Inc.
Synthorx, Inc. (THOR): 3 pipeline candidates · ~31 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
30.5 months
D/E 0.08 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Synthorx, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$18.5M
Quarterly Burn
$14.4M
Runway
30.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| il-2 ai synthorin | Preclinical |
| risperidone | Approved |
| thor-707 | Preclinical |
Frequently asked questions
How many drug candidates are in Synthorx, Inc.'s pipeline?
Synthorx, Inc. (THOR) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Synthorx, Inc.'s lead drug candidate?
Synthorx, Inc.'s most advanced tracked candidate is il-2 ai synthorin (Preclinical) for Autoimmune disorders.
What is Synthorx, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Synthorx, Inc. has approximately 30.5 months of cash runway.
Who is the CEO of Synthorx, Inc.?
La Jolla is the chief executive officer of Synthorx, Inc. (THOR).
Get the full picture on Synthorx, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.